Glenmark Pharma gets USFDA nod for Pimecrolimus Cream; stock up ~1%

Glenmark’s current portfolio consists of 160 products authorized for distribution in the US marketplace and 55 ANDA’s pending approval with the USFDA.

Aug 30, 2019 03:08 IST India Infoline News Service

Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Pimecrolimus Cream, 1%, a generic version of Elidel Cream, 1%, of Bausch Health US, LLC.

According to IQVIA sales data for the 12-month period ending July 2019, the Elidel Cream, 1% market achieved annual sales of approximately $198.8 mn.

Glenmark’s current portfolio consists of 160 products authorized for distribution in the US marketplace and 55 ANDA’s pending approval with the USFDA.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals Ltd is currently trading at Rs384.45, up by Rs0.95 or 0.25% from its previous closing of Rs383.50 on the BSE.

Related Story